[Clinical and metabolic effects of betaxolol (lokren) in treatment of patients with chronic cardiac insufficiency].
Effects were studied of a selective beta-adrenoblocker betaxolol on clinical, hemodynamic, and metabolic indices in patients with chronic cardiac insufficiency (ChCI). A total of 47 patients (27 men and 20 women) with functional class II-III ChCI by the classification of the New-York Association of Cardiologists and the left ventricular ejection fraction less than 40% were examined. The use of betaxolol in the conventional therapy of ChCI has been shown to be of significant clinical benefit in the above patient population, with the improvement in hemodynamic status, the functional class exercise-induces angina alleviated, the left ventricular ejection fraction significantly became greater. Moreover, long-term treatment with betaxolol tends to lower the degree of lipid peroxidation with no adverse effect being exerted on lipid and carbohydrate metabolism.